<abstracts-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/abstract/dtd" xmlns:dn="http://www.elsevier.com/xml/svapi/abstract/dtd" xmlns:ait="http://www.elsevier.com/xml/ani/ait" xmlns:ce="http://www.elsevier.com/xml/ani/common" xmlns:cto="http://www.elsevier.com/xml/cto/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/abstract/scopus_id/85043268328</prism:url><dc:identifier>SCOPUS_ID:85043268328</dc:identifier><eid>2-s2.0-85043268328</eid><pubmed-id>30018520</pubmed-id><prism:doi>10.2478/raon-2018-0010</prism:doi><dc:title>Glioblastoma in patients over 70 years of age</dc:title><prism:aggregationType>Journal</prism:aggregationType><srctype>j</srctype><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><citedby-count>1</citedby-count><prism:publicationName>Radiology and Oncology</prism:publicationName><dc:publisher>
Association of Radiology and Oncology
macvetrev@fvm.ukim.edu.mk
</dc:publisher><source-id>17866</source-id><prism:issn>15813207 13182099</prism:issn><prism:volume>52</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:startingPage>167</prism:startingPage><prism:endingPage>172</prism:endingPage><prism:pageRange>167-172</prism:pageRange><prism:coverDate>2018-01-01</prism:coverDate><openaccess>1</openaccess><openaccessFlag>true</openaccessFlag><dc:creator><author seq="1" auid="6505949136"><ce:initials>U.</ce:initials><ce:indexed-name>Smrdel U.</ce:indexed-name><ce:degrees>MD,PhD</ce:degrees><ce:surname>Smrdel</ce:surname><ce:given-name>Uros</ce:given-name><preferred-name><ce:initials>U.</ce:initials><ce:indexed-name>Smrdel U.</ce:indexed-name><ce:surname>Smrdel</ce:surname><ce:given-name>Uros</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/6505949136</author-url><affiliation id="60000966" href="https://api.elsevier.com/content/affiliation/affiliation_id/60000966"/></author></dc:creator><dc:description><abstract xmlns="" original="y" xml:lang="eng">
<publishercopyright>© 2018 Uros Smrdel, Marija Skoblar Vidmar, Ales Smrdel, published by Sciendo.</publishercopyright>
<ce:para>Glioblastoma has in last 20 years seen the steady increase of incidence, which is most prominent in the group of older patients. These older than 70 years have significantly poorer prognosis than other patients and are considered a distinct group of glioblastoma patients. Modified prognostic factors are being used in these patients and this information is lately supplemented with the genetic and epigenetic information on tumour. The therapy is now often tailored accordingly. The aim of our study was to analyse the current treatment of the glioblastoma patients over 70 years of age to determine the impact of clinical prognostic factors. Among patients treated at the Institute of Oncology Ljubljana between 1997 and 2015, we found that 207 were older than 70 years. We analysed their survival, clinical prognostic factors (age, performance status) treatment modalities (extent of surgery, radiation dose, chemotherapy). Median survival of patients older than 70 years was 5.3 months which was statistically significant inferior to the survival of younger patients (p &lt; 0.001). The clinical prognostic factors that influenced survival the most were performance status (p &lt; 0.001), extent of surgical resection (p &lt; 0.001), addition of temozolomide (p &lt; 0.001) and addition of radiotherapy (p = 0.006). Patients receiving concomitant radiochemotherapy with temozolomide followed by adjuvant temozolomide, had same median survival as patients receiving adjuvant temozolomide after completion of radiotherapy. The increase of the number of older patients with glioblastoma corresponds to the increase in the life expectancy but in Slovenia also to the increased availability of diagnostic procedures. Clinical prognostic markers are helpful in decision on the aggressiveness of treatment. Radiotherapy and temozolomide have the biggest impact on survival, but the radiotherapy dose seems to be of secondary importance. In selected patients, chemotherapy alone might be sufficient to achieve an optimal effect. Patients that were fitter, had more aggressive surgery, and received temozolomide fared the best. The scheduling of the temozolomide seems to have limited impact on survival as in our study, there was no difference weather patients received temozolomide concomitant with radiotherapy or after the radiotherapy. Thus far, our findings corroborate the usefulness of recursive partitioning analysis (RPA) classes in clinical decisions.</ce:para>
</abstract></dc:description><link href="https://api.elsevier.com/content/abstract/scopus_id/85043268328" rel="self"/><link href="https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&amp;scp=85043268328&amp;origin=inward" rel="scopus"/><link href="https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&amp;scp=85043268328&amp;origin=inward" rel="scopus-citedby"/></coredata><affiliation id="60031106" href="https://api.elsevier.com/content/affiliation/affiliation_id/60031106"><affilname>University of Ljubljana</affilname><affiliation-city>Ljubljana</affiliation-city><affiliation-country>Slovenia</affiliation-country></affiliation><affiliation id="60000966" href="https://api.elsevier.com/content/affiliation/affiliation_id/60000966"><affilname>Onkološki inštitut Ljubljana</affilname><affiliation-city>Ljubljana</affiliation-city><affiliation-country>Slovenia</affiliation-country></affiliation><authors><author seq="1" auid="6505949136"><ce:initials>U.</ce:initials><ce:indexed-name>Smrdel U.</ce:indexed-name><ce:degrees>MD,PhD</ce:degrees><ce:surname>Smrdel</ce:surname><ce:given-name>Uros</ce:given-name><preferred-name><ce:initials>U.</ce:initials><ce:indexed-name>Smrdel U.</ce:indexed-name><ce:surname>Smrdel</ce:surname><ce:given-name>Uros</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/6505949136</author-url><affiliation id="60000966" href="https://api.elsevier.com/content/affiliation/affiliation_id/60000966"/></author><author seq="2" auid="55734384300"><ce:initials>M.S.</ce:initials><ce:indexed-name>Vidmar M.S.</ce:indexed-name><ce:surname>Vidmar</ce:surname><ce:given-name>Marija Skoblar</ce:given-name><preferred-name><ce:initials>M.S.</ce:initials><ce:indexed-name>Vidmar M.</ce:indexed-name><ce:surname>Vidmar</ce:surname><ce:given-name>Marija Skoblar</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/55734384300</author-url><affiliation id="60000966" href="https://api.elsevier.com/content/affiliation/affiliation_id/60000966"/></author><author seq="3" auid="6603254309"><ce:initials>A.</ce:initials><ce:indexed-name>Smrdel A.</ce:indexed-name><ce:surname>Smrdel</ce:surname><ce:given-name>Ales</ce:given-name><preferred-name><ce:initials>A.</ce:initials><ce:indexed-name>Smrdel A.</ce:indexed-name><ce:surname>Smrdel</ce:surname><ce:given-name>Ales</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/6603254309</author-url><affiliation id="60031106" href="https://api.elsevier.com/content/affiliation/affiliation_id/60031106"/></author></authors><language xml:lang="eng"/><authkeywords><author-keyword>age group over 70 years</author-keyword><author-keyword>elderly</author-keyword><author-keyword>glioblastoma</author-keyword><author-keyword>prognostic factors</author-keyword><author-keyword>treatment</author-keyword></authkeywords><idxterms/><subject-areas><subject-area code="2730" abbrev="MEDI">Oncology</subject-area><subject-area code="2741" abbrev="MEDI">Radiology, Nuclear Medicine and Imaging</subject-area></subject-areas><item xmlns=""><xocs:meta><xocs:funding-list has-funding-info="1" pui-match="primary"><xocs:funding-addon-generated-timestamp>2018-06-28T17:20:13.788Z</xocs:funding-addon-generated-timestamp><xocs:funding-addon-type>http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/nlp</xocs:funding-addon-type></xocs:funding-list></xocs:meta><ait:process-info><ait:date-delivered day="01" month="02" timestamp="2019-02-01T06:09:54.000054-05:00" year="2019"/><ait:date-sort day="01" month="01" year="2018"/><ait:status stage="S300" state="update" type="core"/></ait:process-info><bibrecord><item-info><copyright type="Elsevier">Copyright 2019 Elsevier B.V., All rights reserved.</copyright><itemidlist>
<ce:doi>10.2478/raon-2018-0010</ce:doi>
<itemid idtype="PUI">621102605</itemid>
<itemid idtype="CAR-ID">909398621</itemid>
<itemid idtype="EMBASE">20180168325</itemid>
<itemid idtype="MEDL">30018520</itemid>
<itemid idtype="REAXYSCAR">20180405473</itemid>
<itemid idtype="SCOPUS">20180695071</itemid>
<itemid idtype="SCP">85043268328</itemid>
<itemid idtype="SGR">85043268328</itemid>
<itemid idtype="PUIsecondary">626151132</itemid>
</itemidlist><history>
<date-created day="31" month="01" timestamp="BST 16:00:32" year="2019"/>
</history><dbcollection>EMBASE</dbcollection><dbcollection>MEDL</dbcollection><dbcollection>REAXYSCAR</dbcollection><dbcollection>SCOPUS</dbcollection><dbcollection>Scopusbase</dbcollection><external-source>PubMed-not-MEDLINE</external-source></item-info><head><citation-info><citation-type code="ar"/><citation-language xml:lang="eng" language="English"/><abstract-language xml:lang="eng" language="English"/><author-keywords>
<author-keyword xml:lang="eng">age group over 70 years</author-keyword>
<author-keyword xml:lang="eng">elderly</author-keyword>
<author-keyword xml:lang="eng">glioblastoma</author-keyword>
<author-keyword xml:lang="eng">prognostic factors</author-keyword>
<author-keyword xml:lang="eng">treatment</author-keyword>
</author-keywords></citation-info><citation-title><titletext original="y" xml:lang="eng" language="English">Glioblastoma in patients over 70 years of age</titletext></citation-title><author-group><author auid="6505949136" seq="1" type="auth"><ce:initials>U.</ce:initials><ce:indexed-name>Smrdel U.</ce:indexed-name><ce:degrees>MD,PhD</ce:degrees><ce:surname>Smrdel</ce:surname><ce:given-name>Uros</ce:given-name><preferred-name>
<ce:initials>U.</ce:initials>
<ce:indexed-name>Smrdel U.</ce:indexed-name>
<ce:surname>Smrdel</ce:surname>
<ce:given-name>Uros</ce:given-name>
</preferred-name></author><author auid="55734384300" seq="2" type="auth"><ce:initials>M.S.</ce:initials><ce:indexed-name>Vidmar M.S.</ce:indexed-name><ce:surname>Vidmar</ce:surname><ce:given-name>Marija Skoblar</ce:given-name><preferred-name>
<ce:initials>M.S.</ce:initials>
<ce:indexed-name>Vidmar M.</ce:indexed-name>
<ce:surname>Vidmar</ce:surname>
<ce:given-name>Marija Skoblar</ce:given-name>
</preferred-name></author><affiliation afid="60000966" country="svn" dptid="103095824"><organization>Department of Radiotherapy</organization><organization>Institute of Oncology Ljubljana</organization><address-part>Zaloška cesta 2</address-part><city>Ljubljana</city><postal-code>1000</postal-code><affiliation-id afid="60000966" dptid="103095824"/><country>Slovenia</country></affiliation></author-group><author-group><author auid="6603254309" seq="3" type="auth"><ce:initials>A.</ce:initials><ce:indexed-name>Smrdel A.</ce:indexed-name><ce:surname>Smrdel</ce:surname><ce:given-name>Ales</ce:given-name><preferred-name>
<ce:initials>A.</ce:initials>
<ce:indexed-name>Smrdel A.</ce:indexed-name>
<ce:surname>Smrdel</ce:surname>
<ce:given-name>Ales</ce:given-name>
</preferred-name></author><affiliation afid="60031106" country="svn"><organization>Faculty of Computer and Information Science</organization><organization>University of Ljubljana</organization><city>Ljubljana</city><affiliation-id afid="60031106"/><country>Slovenia</country></affiliation></author-group><correspondence><person>
<ce:initials>U.</ce:initials>
<ce:indexed-name>Smrdel U.</ce:indexed-name>
<ce:degrees>MD,PhD</ce:degrees>
<ce:surname>Smrdel</ce:surname>
<ce:given-name>Uros</ce:given-name>
</person><affiliation country="svn"><organization>Department of Radiotherapy</organization><organization>Institute of Oncology Ljubljana</organization><address-part>Zaloška cesta 2</address-part><city>Ljubljana</city><postal-code>1000</postal-code><country>Slovenia</country></affiliation></correspondence><abstracts><abstract original="y" xml:lang="eng">
<publishercopyright>© 2018 Uros Smrdel, Marija Skoblar Vidmar, Ales Smrdel, published by Sciendo.</publishercopyright>
<ce:para>Glioblastoma has in last 20 years seen the steady increase of incidence, which is most prominent in the group of older patients. These older than 70 years have significantly poorer prognosis than other patients and are considered a distinct group of glioblastoma patients. Modified prognostic factors are being used in these patients and this information is lately supplemented with the genetic and epigenetic information on tumour. The therapy is now often tailored accordingly. The aim of our study was to analyse the current treatment of the glioblastoma patients over 70 years of age to determine the impact of clinical prognostic factors. Among patients treated at the Institute of Oncology Ljubljana between 1997 and 2015, we found that 207 were older than 70 years. We analysed their survival, clinical prognostic factors (age, performance status) treatment modalities (extent of surgery, radiation dose, chemotherapy). Median survival of patients older than 70 years was 5.3 months which was statistically significant inferior to the survival of younger patients (p &lt; 0.001). The clinical prognostic factors that influenced survival the most were performance status (p &lt; 0.001), extent of surgical resection (p &lt; 0.001), addition of temozolomide (p &lt; 0.001) and addition of radiotherapy (p = 0.006). Patients receiving concomitant radiochemotherapy with temozolomide followed by adjuvant temozolomide, had same median survival as patients receiving adjuvant temozolomide after completion of radiotherapy. The increase of the number of older patients with glioblastoma corresponds to the increase in the life expectancy but in Slovenia also to the increased availability of diagnostic procedures. Clinical prognostic markers are helpful in decision on the aggressiveness of treatment. Radiotherapy and temozolomide have the biggest impact on survival, but the radiotherapy dose seems to be of secondary importance. In selected patients, chemotherapy alone might be sufficient to achieve an optimal effect. Patients that were fitter, had more aggressive surgery, and received temozolomide fared the best. The scheduling of the temozolomide seems to have limited impact on survival as in our study, there was no difference weather patients received temozolomide concomitant with radiotherapy or after the radiotherapy. Thus far, our findings corroborate the usefulness of recursive partitioning analysis (RPA) classes in clinical decisions.</ce:para>
</abstract></abstracts><source country="deu" srcid="17866" type="j"><sourcetitle>Radiology and Oncology</sourcetitle><sourcetitle-abbrev>Radiol. Oncol.</sourcetitle-abbrev><translated-sourcetitle xml:lang="eng">Radiology and Oncology</translated-sourcetitle><issn type="electronic">15813207</issn><issn type="print">13182099</issn><codencode>RONCE</codencode><volisspag>
<voliss issue="2" volume="52"/>
<pagerange first="167" last="172"/>
</volisspag><publicationyear first="2018"/><publicationdate>
<year>2018</year>
<date-text xfab-added="true">2018</date-text></publicationdate><website>
<ce:e-address type="email">http://www.degruyter.com/view/j/raon</ce:e-address>
</website><publisher>
<publishername>Association of Radiology and Oncology</publishername>
<ce:e-address type="email">macvetrev@fvm.ukim.edu.mk</ce:e-address>
</publisher></source><enhancement><classificationgroup><classifications type="EMCLASS">
<classification> <classification-code>14</classification-code> <classification-description>Radiology</classification-description> </classification>
<classification> <classification-code>16</classification-code> <classification-description>Cancer</classification-description> </classification>
<classification> <classification-code>37</classification-code> <classification-description>Drug Literature Index</classification-description> </classification>
<classification> <classification-code>8</classification-code> <classification-description>Neurology and Neurosurgery</classification-description> </classification>
</classifications><classifications type="ASJC">
<classification>2730</classification>
<classification>2741</classification>
</classifications><classifications type="SUBJABBR"><classification>MEDI</classification></classifications></classificationgroup><chemicalgroup>
<chemicals source="esbd">
<chemical>
<chemical-name>temozolomide</chemical-name>
<cas-registry-number>85622-93-1</cas-registry-number>
</chemical>
</chemicals>
</chemicalgroup></enhancement></head><tail><bibliography refcount="23">
<reference id="1">
<ref-info>
<refd-itemidlist>
<itemid idtype="SGR">85048769913</itemid>
</refd-itemidlist>
<ref-sourcetitle>Brain Cancer (C71): 2010-2011 One-, Five-and Tenyear Net Survival (%), Adults Aged 15-99, England &amp; Wales</ref-sourcetitle>
<ref-website>
<ce:e-address type="email">http://info.cancerresearchuk.org/cancerstats/faqs/#How</ce:e-address>
</ref-website>
<ref-text>Cancer Research UK. [cited 2017 Avg 15]</ref-text>
</ref-info>
<ref-fulltext>Cancer Research UK. Brain cancer (C71): 2010-2011. One-, five-and tenyear net survival (%), adults aged 15-99, England &amp; Wales. [cited 2017 Avg 15]. Available at: http://info. cancerresearchuk. org/cancerstats/faqs/#How.</ref-fulltext>
</reference>
<reference id="2">
<ref-info>
<ref-title>
<ref-titletext>Are reported increases in incidence of primary CNS tumours real An analysis of longitudinal trends in England, 1979-2003</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="DOI">10.1016/j.ejca.2010.02.007</itemid>
<itemid idtype="SGR">77952672750</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>R.S.</ce:initials>
<ce:indexed-name>Arora R.S.</ce:indexed-name>
<ce:surname>Arora</ce:surname>
</author>
<author seq="2">
<ce:initials>R.D.</ce:initials>
<ce:indexed-name>Alston R.D.</ce:indexed-name>
<ce:surname>Alston</ce:surname>
</author>
<author seq="3">
<ce:initials>T.O.</ce:initials>
<ce:indexed-name>Eden T.O.</ce:indexed-name>
<ce:surname>Eden</ce:surname>
</author>
<author seq="4">
<ce:initials>E.J.</ce:initials>
<ce:indexed-name>Estlin E.J.</ce:indexed-name>
<ce:surname>Estlin</ce:surname>
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:indexed-name>Moran A.</ce:indexed-name>
<ce:surname>Moran</ce:surname>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:indexed-name>Geraci M.</ce:indexed-name>
<ce:surname>Geraci</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Eur J Cancer</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<ref-volisspag>
<voliss volume="46"/>
<pagerange first="1607" last="1616"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>Arora RS, Alston RD, Eden TO, Estlin EJ, Moran A, Geraci M, et al. Are reported increases in incidence of primary CNS tumours real An analysis of longitudinal trends in England, 1979-2003. Eur J Cancer 2010; 46: 1607-16. doi: 10. 1016/j. ejca. 2010. 02. 007</ref-fulltext>
</reference>
<reference id="3">
<ref-info>
<ref-title>
<ref-titletext>CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2005-2009</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="DOI">10.1093/neuonc/nos218</itemid>
<itemid idtype="SGR">84868023931</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>T.A.</ce:initials>
<ce:indexed-name>Dolecek T.A.</ce:indexed-name>
<ce:surname>Dolecek</ce:surname>
</author>
<author seq="2">
<ce:initials>J.M.</ce:initials>
<ce:indexed-name>Propp J.M.</ce:indexed-name>
<ce:surname>Propp</ce:surname>
</author>
<author seq="3">
<ce:initials>N.E.</ce:initials>
<ce:indexed-name>Stroup N.E.</ce:indexed-name>
<ce:surname>Stroup</ce:surname>
</author>
<author seq="4">
<ce:initials>C.</ce:initials>
<ce:indexed-name>Kruchko C.</ce:indexed-name>
<ce:surname>Kruchko</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Neuro Oncol</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<ref-volisspag>
<voliss volume="14"/>
<pagerange first="v1" last="49"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol 2012; 14(Suppl 5): v1-49. doi: 10. 1093/neuonc/nos218</ref-fulltext>
</reference>
<reference id="4">
<ref-info>
<ref-title>
<ref-titletext>CBTRUS statistical report: Primary brain and central nervous aystem tumors diagnosed in the United States in 2008-2012</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="DOI">10.1093/neuonc/nov189</itemid>
<itemid idtype="SGR">85020249099</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>Q.T.</ce:initials>
<ce:indexed-name>Ostrom Q.T.</ce:indexed-name>
<ce:surname>Ostrom</ce:surname>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:indexed-name>Gittleman H.</ce:indexed-name>
<ce:surname>Gittleman</ce:surname>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:indexed-name>Fulop J.</ce:indexed-name>
<ce:surname>Fulop</ce:surname>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:indexed-name>Liu M.</ce:indexed-name>
<ce:surname>Liu</ce:surname>
</author>
<author seq="5">
<ce:initials>R.</ce:initials>
<ce:indexed-name>Blanda R.</ce:indexed-name>
<ce:surname>Blanda</ce:surname>
</author>
<author seq="6">
<ce:initials>C.</ce:initials>
<ce:indexed-name>Kromer C.</ce:indexed-name>
<ce:surname>Kromer</ce:surname>
</author>
<author seq="7">
<ce:initials>Y.</ce:initials>
<ce:indexed-name>Wolinsky Y.</ce:indexed-name>
<ce:surname>Wolinsky</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Neuro Oncol</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<ref-volisspag>
<voliss volume="17"/>
<pagerange first="iv1" last="62"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, Wolinsky Y, et al. CBTRUS statistical report: primary brain and central nervous aystem tumors diagnosed in the United States in 2008-2012. Neuro Oncol 2015; 17(Suppl 4): iv1-62. doi: 10. 1093/neuonc/nov189</ref-fulltext>
</reference>
<reference id="5">
<ref-info>
<refd-itemidlist>
<itemid idtype="SGR">85048828782</itemid>
</refd-itemidlist>
<ref-sourcetitle>Cancer Incidence in Slovenia 1997-2006</ref-sourcetitle>
<ref-publicationyear first="2000" last="2009"/>
<ref-text>Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Cancer Registry of Republic of Slovenia</ref-text>
</ref-info>
<ref-fulltext>Cancer incidence in Slovenia 1997-2006. Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Cancer Registry of Republic of Slovenia; 2000-2009.</ref-fulltext>
</reference>
<reference id="6">
<ref-info>
<refd-itemidlist>
<itemid idtype="SGR">81755170618</itemid>
</refd-itemidlist>
<ref-sourcetitle>Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry</ref-sourcetitle>
<ref-publicationyear first="2010" last="2014"/>
<ref-text>Cancer in Slovenia 2007-11, Cancer Registry of Republic of Slovenia</ref-text>
</ref-info>
<ref-fulltext>Cancer in Slovenia 2007-11. Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Cancer Registry of Republic of Slovenia; 2010-2014.</ref-fulltext>
</reference>
<reference id="7">
<ref-info>
<ref-title>
<ref-titletext>Glioblastoma patients in Slovenia from 1997 to 2008</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="DOI">10.2478/raon-2014-0002</itemid>
<itemid idtype="SGR">84893767490</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>U.</ce:initials>
<ce:indexed-name>Smrdel U.</ce:indexed-name>
<ce:surname>Smrdel</ce:surname>
</author>
<author seq="2">
<ce:initials>V.</ce:initials>
<ce:indexed-name>Kovac V.</ce:indexed-name>
<ce:surname>Kovac</ce:surname>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:indexed-name>Popovic M.</ce:indexed-name>
<ce:surname>Popovic</ce:surname>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:indexed-name>Zwitter M.</ce:indexed-name>
<ce:surname>Zwitter</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Radiol Oncol</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<ref-volisspag>
<voliss volume="48"/>
<pagerange first="72" last="79"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>Smrdel U, Kovac V, Popovic M, Zwitter M. Glioblastoma patients in Slovenia from 1997 to 2008. Radiol Oncol 2014; 48: 72-9. doi: 10. 2478/raon-2014-0002</ref-fulltext>
</reference>
<reference id="8">
<ref-info>
<ref-title>
<ref-titletext>Genetic pathways to glioblastoma: A population-based study</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="DOI">10.1158/0008-5472.CAN-04-1337</itemid>
<itemid idtype="SGR">4944255253</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:indexed-name>Ohgaki H.</ce:indexed-name>
<ce:surname>Ohgaki</ce:surname>
</author>
<author seq="2">
<ce:initials>P.</ce:initials>
<ce:indexed-name>Dessen P.</ce:indexed-name>
<ce:surname>Dessen</ce:surname>
</author>
<author seq="3">
<ce:initials>B.</ce:initials>
<ce:indexed-name>Jourde B.</ce:indexed-name>
<ce:surname>Jourde</ce:surname>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:indexed-name>Horstmann S.</ce:indexed-name>
<ce:surname>Horstmann</ce:surname>
</author>
<author seq="5">
<ce:initials>T.</ce:initials>
<ce:indexed-name>Nishikawa T.</ce:indexed-name>
<ce:surname>Nishikawa</ce:surname>
</author>
<author seq="6">
<ce:initials>P.-L.</ce:initials>
<ce:indexed-name>Di Patre P.-L.</ce:indexed-name>
<ce:surname>Di Patre</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2004"/>
<ref-volisspag>
<voliss volume="64"/>
<pagerange first="6892" last="6899"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre P-L, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res 2004; 64: 6892-9. doi: 10. 1158/0008-5472. CAN-04-1337</ref-fulltext>
</reference>
<reference id="9">
<ref-info>
<ref-title>
<ref-titletext>Delay in the diagnosis of glioblastoma multiforme: Is age a factor?</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">0029979044</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>A.D.</ce:initials>
<ce:indexed-name>Steinfeld A.D.</ce:indexed-name>
<ce:surname>Steinfeld</ce:surname>
</author>
<author seq="2">
<ce:initials>B.</ce:initials>
<ce:indexed-name>Donahue B.</ce:indexed-name>
<ce:surname>Donahue</ce:surname>
</author>
<author seq="3">
<ce:initials>I.</ce:initials>
<ce:indexed-name>Walker I.</ce:indexed-name>
<ce:surname>Walker</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Invest</ref-sourcetitle>
<ref-publicationyear first="1996"/>
<ref-volisspag>
<voliss volume="14"/>
<pagerange first="317" last="319"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>Steinfeld AD, Donahue B, Walker I. Delay in the diagnosis of glioblastoma multiforme: is age a factor? Cancer Invest 1996; 14: 317-9.</ref-fulltext>
</reference>
<reference id="10">
<ref-info>
<ref-title>
<ref-titletext>Molecular and genomic alterations in glioblastoma multiforme</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="DOI">10.1016/j.ajpath.2015.02.023</itemid>
<itemid idtype="SGR">84931449647</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>I.</ce:initials>
<ce:indexed-name>Crespo I.</ce:indexed-name>
<ce:surname>Crespo</ce:surname>
</author>
<author seq="2">
<ce:initials>A.L.</ce:initials>
<ce:indexed-name>Vital A.L.</ce:indexed-name>
<ce:surname>Vital</ce:surname>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:indexed-name>Gonzalez-Tablas M.</ce:indexed-name>
<ce:surname>Gonzalez-Tablas</ce:surname>
</author>
<author seq="4">
<ce:initials>M.C.</ce:initials>
<ce:indexed-name>Patino Del M.C.</ce:indexed-name>
<ce:surname>Patino Del</ce:surname>
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:indexed-name>Otero A.</ce:indexed-name>
<ce:surname>Otero</ce:surname>
</author>
<author seq="6">
<ce:initials>M.C.</ce:initials>
<ce:indexed-name>Lopes M.C.</ce:indexed-name>
<ce:surname>Lopes</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Am J Pathol</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<ref-volisspag>
<voliss volume="185"/>
<pagerange first="1820" last="1833"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>Crespo I, Vital AL, Gonzalez-Tablas M, Patino M del C, Otero A, Lopes MC, et al. Molecular and genomic alterations in glioblastoma multiforme. Am J Pathol 2015; 185: 1820-33. doi: 10. 1016/j. ajpath. 2015. 02. 023</ref-fulltext>
</reference>
<reference id="11">
<ref-info>
<ref-title>
<ref-titletext>High-grade astrocytomas</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="SGR">85048789460</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>J.F.</ce:initials>
<ce:indexed-name>De Groot J.F.</ce:indexed-name>
<ce:surname>De Groot</ce:surname>
</author>
<author seq="2">
<ce:initials>K.D.C.H.</ce:initials>
<ce:indexed-name>Aldape K.D.C.H.</ce:indexed-name>
<ce:surname>Aldape</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Principles of Neuro-oncology</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<ref-volisspag>
<pagerange first="259" last="288"/>
</ref-volisspag>
<ref-text>Schiff D, On B, editors. New York: McGraw Hill</ref-text>
</ref-info>
<ref-fulltext>De Groot JF, Aldape KD CH. High-grade astrocytomas. In: Schiff D, On B, editors. Principles of neuro-oncology. New York: McGraw Hill; 2005. p. 259-88.</ref-fulltext>
</reference>
<reference id="12">
<ref-info>
<ref-title>
<ref-titletext>[Elderly patients with glioblastoma: State of the art] [French]</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="DOI">10.1016/j.bulcan.2015.02.002</itemid>
<itemid idtype="SGR">84927718009</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:indexed-name>Biau J.</ce:indexed-name>
<ce:surname>Biau</ce:surname>
</author>
<author seq="2">
<ce:initials>P.</ce:initials>
<ce:indexed-name>Dalloz P.</ce:indexed-name>
<ce:surname>Dalloz</ce:surname>
</author>
<author seq="3">
<ce:initials>X.</ce:initials>
<ce:indexed-name>Durando X.</ce:indexed-name>
<ce:surname>Durando</ce:surname>
</author>
<author seq="4">
<ce:initials>M.O.</ce:initials>
<ce:indexed-name>Hager M.O.</ce:indexed-name>
<ce:surname>Hager</ce:surname>
</author>
<author seq="5">
<ce:initials>Z.G.</ce:initials>
<ce:indexed-name>Ouedraogo Z.G.</ce:indexed-name>
<ce:surname>Ouédraogo</ce:surname>
</author>
<author seq="6">
<ce:initials>T.</ce:initials>
<ce:indexed-name>Khalil T.</ce:indexed-name>
<ce:surname>Khalil</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Bull Cancer</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<ref-volisspag>
<voliss volume="102"/>
<pagerange first="277" last="286"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>Biau J, Dalloz P, Durando X, Hager MO, Ouédraogo ZG, Khalil T, et al. [Elderly patients with glioblastoma: state of the art]. [French]. Bull Cancer2015; 102: 277-86. doi: 10. 1016/j. bulcan. 2015. 02. 002</ref-fulltext>
</reference>
<reference id="13">
<ref-info>
<ref-title>
<ref-titletext>Validation and simplification of the Radiation Therapy Oncology Group recursive partitioning analysis classification for glioblastoma</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="DOI">10.1016/j.ijrobp.2010.06.012</itemid>
<itemid idtype="SGR">80053613758</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:indexed-name>Li J.</ce:indexed-name>
<ce:surname>Li</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:indexed-name>Wang M.</ce:indexed-name>
<ce:surname>Wang</ce:surname>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:indexed-name>Won M.</ce:indexed-name>
<ce:surname>Won</ce:surname>
</author>
<author seq="4">
<ce:initials>E.G.</ce:initials>
<ce:indexed-name>Shaw E.G.</ce:indexed-name>
<ce:surname>Shaw</ce:surname>
</author>
<author seq="5">
<ce:initials>C.</ce:initials>
<ce:indexed-name>Coughlin C.</ce:indexed-name>
<ce:surname>Coughlin</ce:surname>
</author>
<author seq="6">
<ce:initials>W.J.</ce:initials>
<ce:indexed-name>Curran W.J.</ce:indexed-name>
<ce:surname>Curran</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Int J Radiat Oncol Biol Phys</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<ref-volisspag>
<voliss volume="81"/>
<pagerange first="623" last="630"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>Li J, Wang M, Won M, Shaw EG, Coughlin C, Curran WJ, et al. Validation and simplification of the Radiation Therapy Oncology Group recursive partitioning analysis classification for glioblastoma. Int J Radiat Oncol Biol Phys 2011; 81: 623-30. doi: 10. 1016/j. ijrobp. 2010. 06. 012</ref-fulltext>
</reference>
<reference id="14">
<ref-info>
<ref-title>
<ref-titletext>Recursive partitioning analysis of prognostic factors for glioblastoma patients aged 70 years or older</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="DOI">10.1002/cncr.27570</itemid>
<itemid idtype="SGR">84868122254</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>J.G.</ce:initials>
<ce:indexed-name>Scott J.G.</ce:indexed-name>
<ce:surname>Scott</ce:surname>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:indexed-name>Bauchet L.</ce:indexed-name>
<ce:surname>Bauchet</ce:surname>
</author>
<author seq="3">
<ce:initials>T.J.</ce:initials>
<ce:indexed-name>Fraum T.J.</ce:indexed-name>
<ce:surname>Fraum</ce:surname>
</author>
<author seq="4">
<ce:initials>L.</ce:initials>
<ce:indexed-name>Nayak L.</ce:indexed-name>
<ce:surname>Nayak</ce:surname>
</author>
<author seq="5">
<ce:initials>A.R.</ce:initials>
<ce:indexed-name>Cooper A.R.</ce:indexed-name>
<ce:surname>Cooper</ce:surname>
</author>
<author seq="6">
<ce:initials>S.T.</ce:initials>
<ce:indexed-name>Chao S.T.</ce:indexed-name>
<ce:surname>Chao</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Cancer</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<ref-volisspag>
<voliss volume="118"/>
<pagerange first="5595" last="5600"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>Scott JG, Bauchet L, Fraum TJ, Nayak L, Cooper AR, Chao ST, et al. Recursive partitioning analysis of prognostic factors for glioblastoma patients aged 70 years or older. Cancer 2012; 118: 5595-600. doi: 10. 1002/cncr. 27570</ref-fulltext>
</reference>
<reference id="15">
<ref-info>
<ref-title>
<ref-titletext>Treatment options and outcomes for glioblastoma in the elderly patient</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="DOI">10.2147/CIA.S44259</itemid>
<itemid idtype="SGR">84896886566</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>N.D.</ce:initials>
<ce:indexed-name>Arvold N.D.</ce:indexed-name>
<ce:surname>Arvold</ce:surname>
</author>
<author seq="2">
<ce:initials>D.A.</ce:initials>
<ce:indexed-name>Reardon D.A.</ce:indexed-name>
<ce:surname>Reardon</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Clin Interv Aging</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<ref-volisspag>
<voliss volume="9"/>
<pagerange first="357" last="367"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>Arvold ND, Reardon DA. Treatment options and outcomes for glioblastoma in the elderly patient. Clin Interv Aging 2014; 9: 357-67. doi: 10. 2147/CIA. S44259</ref-fulltext>
</reference>
<reference id="16">
<ref-info>
<ref-title>
<ref-titletext>Incidence trends of adult primary intracerebral tumors in four Nordic countries</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="DOI">10.1002/ijc.11578</itemid>
<itemid idtype="SGR">10744229352</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:indexed-name>Lonn S.</ce:indexed-name>
<ce:surname>Lönn</ce:surname>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:indexed-name>Klaeboe L.</ce:indexed-name>
<ce:surname>Klaeboe</ce:surname>
</author>
<author seq="3">
<ce:initials>P.</ce:initials>
<ce:indexed-name>Hall P.</ce:indexed-name>
<ce:surname>Hall</ce:surname>
</author>
<author seq="4">
<ce:initials>T.</ce:initials>
<ce:indexed-name>Mathiesen T.</ce:indexed-name>
<ce:surname>Mathiesen</ce:surname>
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:indexed-name>Auvinen A.</ce:indexed-name>
<ce:surname>Auvinen</ce:surname>
</author>
<author seq="6">
<ce:initials>H.C.</ce:initials>
<ce:indexed-name>Christensen H.C.</ce:indexed-name>
<ce:surname>Christensen</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Int J Cancer</ref-sourcetitle>
<ref-publicationyear first="2004"/>
<ref-volisspag>
<voliss volume="108"/>
<pagerange first="450" last="455"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>Lönn S, Klaeboe L, Hall P, Mathiesen T, Auvinen A, Christensen HC, et al. Incidence trends of adult primary intracerebral tumors in four Nordic countries. Int J Cancer 2004; 108: 450-5. doi: 10. 1002/ijc. 11578</ref-fulltext>
</reference>
<reference id="17">
<ref-info>
<refd-itemidlist>
<itemid idtype="SGR">84875935270</itemid>
</refd-itemidlist>
<ref-sourcetitle>Births and Deaths</ref-sourcetitle>
<ref-website>
<ce:e-address type="email">http://www.stat.si/StatWeb/Field/Index/17/95</ce:e-address>
</ref-website>
<ref-text>Statistical Office, Republic of Slovenia [Internet]. [cited 2017 Nov 19]</ref-text>
</ref-info>
<ref-fulltext>Statistical Office, Republic of Slovenia. Births and deaths. [Internet]. [cited 2017 Nov 19]. Available at: http://www. stat. si/StatWeb/Field/Index/17/95</ref-fulltext>
</reference>
<reference id="18">
<ref-info>
<refd-itemidlist>
<itemid idtype="SGR">85040527558</itemid>
</refd-itemidlist>
<ref-sourcetitle>Health at A Glance 2017</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<ref-website>
<ce:e-address type="email">http://www.oecd-ilibrary.org/socialissues-migration-health/health-at-a-glance-2017_health_glance-2017-en</ce:e-address>
</ref-website>
<ref-text>OECDiLibrary [Internet]. OECD Publishing [cited 2017 Nov 19]</ref-text>
</ref-info>
<ref-fulltext>OECDiLibrary. Health at a glance 2017. [Internet]. OECD Publishing; 2017 [cited 2017 Nov 19]. Available at: http://www. oecd-ilibrary. org/socialissues-migration-health/health-at-a-glance-2017-health-glance-2017-en</ref-fulltext>
</reference>
<reference id="19">
<ref-info>
<ref-title>
<ref-titletext>Elderly patients with glioblastoma: The treatment challenge</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="DOI">10.1586/14737175.2013.840419</itemid>
<itemid idtype="SGR">84886876599</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:indexed-name>Fiorentino A.</ce:indexed-name>
<ce:surname>Fiorentino</ce:surname>
</author>
<author seq="2">
<ce:initials>P.</ce:initials>
<ce:indexed-name>De Bonis P.</ce:indexed-name>
<ce:surname>De Bonis</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:indexed-name>Chiesa S.</ce:indexed-name>
<ce:surname>Chiesa</ce:surname>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:indexed-name>Balducci M.</ce:indexed-name>
<ce:surname>Balducci</ce:surname>
</author>
<author seq="5">
<ce:initials>V.</ce:initials>
<ce:indexed-name>Fusco V.</ce:indexed-name>
<ce:surname>Fusco</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Expert Rev Neurother</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<ref-volisspag>
<voliss volume="13"/>
<pagerange first="1099" last="1105"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>Fiorentino A, De Bonis P, Chiesa S, Balducci M, Fusco V. Elderly patients with glioblastoma: the treatment challenge. Expert Rev Neurother 2013; 13: 1099-105. doi: 10. 1586/14737175. 2013. 840419</ref-fulltext>
</reference>
<reference id="20">
<ref-info>
<ref-title>
<ref-titletext>Treatment options and outcomes for glioblastoma in the elderly patient</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="DOI">10.2147/CIA.S44259</itemid>
<itemid idtype="SGR">84896886566</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:indexed-name>Reardon D.</ce:indexed-name>
<ce:surname>Reardon</ce:surname>
</author>
<author seq="2">
<ce:initials>N.</ce:initials>
<ce:indexed-name>Arvold N.</ce:indexed-name>
<ce:surname>Arvold</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Clin Interv Aging</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<ref-volisspag>
<voliss volume="9"/>
<pagerange first="357" last="367"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>Reardon D, Arvold N. Treatment options and outcomes for glioblastoma in the elderly patient. Clin Interv Aging 2014; 9: 357-67. doi: 10. 2147/CIA. S44259</ref-fulltext>
</reference>
<reference id="21">
<ref-info>
<ref-title>
<ref-titletext>Oncological patterns of care and outcomes for 265 elderly patients with newly diagnosed glioblastoma in France</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="DOI">10.1007/s10143-014-0528-8</itemid>
<itemid idtype="SGR">84904572669</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:indexed-name>Zouaoui S.</ce:indexed-name>
<ce:surname>Zouaoui</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:indexed-name>Darlix A.</ce:indexed-name>
<ce:surname>Darlix</ce:surname>
</author>
<author seq="3">
<ce:initials>P.</ce:initials>
<ce:indexed-name>Fabbro-Peray P.</ce:indexed-name>
<ce:surname>Fabbro-Peray</ce:surname>
</author>
<author seq="4">
<ce:initials>H.</ce:initials>
<ce:indexed-name>Mathieu-Daude H.</ce:indexed-name>
<ce:surname>Mathieu-Daudé</ce:surname>
</author>
<author seq="5">
<ce:initials>V.</ce:initials>
<ce:indexed-name>Rigau V.</ce:indexed-name>
<ce:surname>Rigau</ce:surname>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:indexed-name>Fabro M.</ce:indexed-name>
<ce:surname>Fabro</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Neurosurg Rev</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<ref-volisspag>
<voliss volume="3"/>
<pagerange first="415" last="423"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>Zouaoui S, Darlix A, Fabbro-Peray P, Mathieu-Daudé H, Rigau V, Fabro M, et al. Oncological patterns of care and outcomes for 265 elderly patients with newly diagnosed glioblastoma in France. Neurosurg Rev 2014; 3: 415-23. doi: 10. 1007/s10143-014-0528-8</ref-fulltext>
</reference>
<reference id="22">
<ref-info>
<ref-title>
<ref-titletext>Radiotherapy for glioblastoma in the elderly</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="DOI">10.1056/NEJMoa065901</itemid>
<itemid idtype="SGR">34247100159</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:indexed-name>Keime-Guibert F.</ce:indexed-name>
<ce:surname>Keime-Guibert</ce:surname>
</author>
<author seq="2">
<ce:initials>O.</ce:initials>
<ce:indexed-name>Chinot O.</ce:indexed-name>
<ce:surname>Chinot</ce:surname>
</author>
<author seq="3">
<ce:initials>L.</ce:initials>
<ce:indexed-name>Taillandier L.</ce:indexed-name>
<ce:surname>Taillandier</ce:surname>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:indexed-name>Cartalat-Carel S.</ce:indexed-name>
<ce:surname>Cartalat-Carel</ce:surname>
</author>
<author seq="5">
<ce:initials>M.</ce:initials>
<ce:indexed-name>Frenay M.</ce:indexed-name>
<ce:surname>Frenay</ce:surname>
</author>
<author seq="6">
<ce:initials>G.</ce:initials>
<ce:indexed-name>Kantor G.</ce:indexed-name>
<ce:surname>Kantor</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>N Eng J Med</ref-sourcetitle>
<ref-publicationyear first="2007"/>
<ref-volisspag>
<voliss volume="356"/>
<pagerange first="1527" last="1535"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>Keime-Guibert F, Chinot O, Taillandier L, Cartalat-Carel S, Frenay M, Kantor G, et al. Radiotherapy for glioblastoma in the elderly. N Eng J Med 2007; 356: 1527-35. doi: 10. 1056/NEJMoa065901</ref-fulltext>
</reference>
<reference id="23">
<ref-info>
<ref-title>
<ref-titletext>Longterm survival in glioblastoma: Methyl guanine methyl transferase (MGMT) promoter methylation as independent favourable prognostic factor</ref-titletext>
</ref-title>
<refd-itemidlist>
<itemid idtype="DOI">10.1515/raon-2015-0041</itemid>
<itemid idtype="SGR">84989959466</itemid>
</refd-itemidlist>
<ref-authors>
<author seq="1">
<ce:initials>U.</ce:initials>
<ce:indexed-name>Smrdel U.</ce:indexed-name>
<ce:surname>Smrdel</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:indexed-name>Popovic M.</ce:indexed-name>
<ce:surname>Popovic</ce:surname>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:indexed-name>Zwitter M.</ce:indexed-name>
<ce:surname>Zwitter</ce:surname>
</author>
<author seq="4">
<ce:initials>E.</ce:initials>
<ce:indexed-name>Bostjancic E.</ce:indexed-name>
<ce:surname>Bostjancic</ce:surname>
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:indexed-name>Zupan A.</ce:indexed-name>
<ce:surname>Zupan</ce:surname>
</author>
<author seq="6">
<ce:initials>V.</ce:initials>
<ce:indexed-name>Kovac V.</ce:indexed-name>
<ce:surname>Kovac</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Radiol Oncol</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<ref-volisspag>
<voliss volume="50"/>
<pagerange first="394" last="401"/>
</ref-volisspag>
</ref-info>
<ref-fulltext>Smrdel U, Popovic M, Zwitter M, Bostjancic E, Zupan A, Kovac V, et al. Longterm survival in glioblastoma: methyl guanine methyl transferase (MGMT) promoter methylation as independent favourable prognostic factor. Radiol Oncol 2016; 50: 394-401. doi: 10. 1515/raon-2015-0041</ref-fulltext>
</reference>
</bibliography></tail></bibrecord></item></abstracts-retrieval-response>